RxDoctor Payments Data

Wendy Beckwith, NP

Nurse Practitioner · Battle Creek, MINPI 1104176460

Payments from drug & device makers

$1,218in general payments, 2019–2025

Across 47 payments — averaging $25.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$344
  • Coloplast$162
  • Endo USA, Inc.$155
  • Astellas Pharma US Inc$139
  • Sumitomo Pharma America, Inc.$89
  • Shionogi Inc$39
  • plus $290 from 13 others

What the payments were for

  • Food & beverage$1,05487%
  • Education$16413%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,218 in reported general payments places this provider in the 80th percentile of 3,351 nurse practitioner providers in Michigan.

See all nurse practitioner providers in Michigan

Medicare billing

Part B allowed, 2024
$39,309
Medicare patients
329
Services billed
692

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron201$175,535
Solifenacin Succinate189$10,131
Estradiol100$8,608
Mirabegron ErMirabegron15$5,807
Tolterodine Tartrate ErTolterodine Tartrate37$3,410
Methenamine Hippurate43$2,908
Tamsulosin Hcl158$2,888
Desmopressin Acetate15$2,676
Alfuzosin Hcl ErAlfuzosin Hcl95$2,314
Trimethoprim35$861
Trospium Chloride12$850
Finasteride44$774
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst51$763
Dutasteride17$655
Testosterone Cypionate22$379

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$139$175,535201 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,351 nurse practitioner providers in Michigan.

Other nurse practitioner in Battle Creek

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →